TIDMSTX

RNS Number : 2111I

Shield Therapeutics PLC

11 August 2021

Shield Therapeutics plc

("Shield or the "Company" or the "Group")

Notice of Results

London, UK, 11 August 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru(R)/Accrufer(R) (ferric maltol), will announce its interim results for the six months ended 30 June 2021 on Tuesday 17 August 2021.

Analyst briefing

A briefing open to analysts will take place remotely via video conference call on Tuesday 17 August 2021 at 14.00 (BST). If you would like the details of this call please contact Walbrook PR on shield@walbrookpr.com .

For further information, please contact:

 
 Shield Therapeutics plc                                     +44 (0) 191 511 8500 
 Greg Madison (CEO) 
  Hans-Peter Rudolf (CFO) 
 
 Peel Hunt LLP - Nominated Adviser & Joint 
  Broker                                                     +44 (0) 20 7148 8900 
 James Steel / Christopher Golden 
 
 finnCap Ltd - Joint Broker                                  +44 (0) 20 7220 0500 
 Geoff Nash / Alice Lane/ George Dollemore 
 
 Walbrook PR - Financial PR & IR Adviser                     +44 (0) 20 7933 8780 
 Paul McManus / Lianne Cawthorne/ Alice                  or shield@walbrookpr.com 
  Woodings

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru (R) /Accrufer (R) (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru(R)/Accrufer(R), has been approved for use in the United States, European Union, UK, Switzerland and Australia and has exclusive IP rights until the mid-2030s. The Group is currently launching Accrufer(R) in the US. Feraccru(R) is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORBLGDIDGBDGBG

(END) Dow Jones Newswires

August 11, 2021 02:00 ET (06:00 GMT)

Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Shield Therapeutics.
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Shield Therapeutics.